Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Year-over-year book value per share growth
Percentile
P5
Near historical low
vs 5Y Ago
-1.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -90.35% |
| Q3 2025 | 56.77% |
| Q2 2025 | -29.94% |
| Q1 2025 | 35.99% |
| Q4 2024 | -19.35% |
| Q3 2024 | 56.74% |
| Q2 2024 | 62.55% |
| Q1 2024 | 115.69% |
| Q4 2023 | -65.61% |
| Q3 2023 | 64.69% |
| Q2 2023 | 135.10% |
| Q1 2023 | -61.14% |
| Q4 2022 | 76.67% |
| Q3 2022 | -66.57% |
| Q2 2022 | 12.42% |
| Q1 2022 | 34.60% |
| Q4 2021 | -29.18% |
| Q3 2021 | 135.99% |
| Q2 2021 | 71.52% |
| Q1 2021 | -56.17% |
| Q4 2020 | 54.25% |
| Q3 2020 | -6.68% |
| Q2 2020 | 83.57% |
| Q1 2020 | -34.97% |
| Q4 2019 | -61.25% |
| Q3 2019 | -6.12% |
| Q2 2019 | -0.46% |
| Q1 2019 | 0.08% |
| Q4 2018 | 7.79% |
| Q3 2018 | -6.21% |
| Q2 2018 | -4.44% |
| Q1 2018 | 26.37% |
| Q4 2017 | 186.77% |
| Q3 2017 | 18.13% |
| Q2 2017 | 195.42% |
| Q1 2017 | -74.33% |
| Q4 2016 | -173.81% |
| Q3 2016 | -222.91% |
| Q2 2016 | -66.43% |
| Q1 2016 | -31.68% |